Devyser Diagnostics AB (publ) (“Devyser”) has appointed Carnegie Investment Bank AB (publ) (”Carnegie”) as liquidity provider for the company’s shares listed on Nasdaq First North Growth…
Devyser has today been certified under the new, more comprehensive IVD Regulation that came into force on May 26, 2022. The certification, issued by the notified body TÜV SÜD, covers…
"Devyser reported another quarter of strong organic growth, which again saw record-breaking sales. The gross margin remained high. Both sales and margins have the potential for further…
On September 1, Camilla Wiberg will take up the newly established position as Chief HR Officer (CHRO) and become a member of the Devyser group management. In Devyser’s current growth…
On Wednesday August 24, at 09.00 CET, Devyser Diagnostics AB will host an online presentation of its Q2 2022 interim report (which will have been published earlier on August 24, at 08.00…
Devyser has been awarded a tender from Héma-Québec, in Québec, Canada, for its non-invasive fetal RHD detection product, used to determine fetal RHD status from maternal plasma in early…
The Annual General Meeting of Devyser Diagnostics AB (publ) (“Devyser” or the “Company”) was held on Wednesday, 11 May 2022. The Annual General Meeting was conducted by way of postal…
"Despite a turbulent environment, we are pleased that the first quarter of 2022 has continued in the same positive direction as we saw in 2021. Both sales and gross margin set new records…
On Wednesday May 11, at 09.00 CET, Devyser Diagnostics AB will host an online presentation of its Q1 2022 interim report (which will have been published earlier on May 11, at 08.00 CET).…
Devyser announces a strengthening of its commercial organization with the appointment of Theis Kipling as Chief Commercial Officer (CCO) with global responsibility for sales, marketing,…
